Abstracts tagged "Biologicals"

Abstract Number: L05 • ACR Convergence 2024
Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels
Christian Schwabe¹, Orit Cohen Barak², Alexandra Cole³, Hadar Reuveni², Liron Shelev², Liora Blinder-Haddad² and Nicola Dalbeth⁴, ¹NZCR, Auckland, New Zealand, ²Protalix Ltd, Karmiel, Israel, ³NZCR, Christchurch, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
Abstract Number: L13 • ACR Convergence 2024
Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort
Zahi Touma¹, Ian Bruce², Richard A. Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Kellyn Arnold⁸, Hopin Lee⁸, Eleanor Ralphs⁸, Danuta Kielar⁹, Aleksander Bedenkov⁹ and Miina Waratani⁹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Queen's University Belfast, Belfast, United Kingdom, ³Northwell Health, Manhasset, NY, ⁴Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶Astrazeneca, Mississauga, ON, Canada, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸IQVIA, London, United Kingdom, ⁹Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on…
Abstract Number: L19 • ACR Convergence 2024
Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials
Alexei Grom¹, Uwe Ullman², Adnan Mahmood³, Josefin Blomkvist³, Brian Jamieson⁴ and Fabrizio De Benedetti⁵, ¹Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ²Sobi, Basel, Switzerland, ³Sobi, Stockholm, Sweden, ⁴Sobi, Inc., Morrisville, NC, ⁵Bambino Gesu Children's Hospital, Rome, Italy
Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…
Abstract Number: 0222 • ACR Convergence 2024
The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ummugulsum Gazel¹, Ozun Bayindir Tsechelidis³, Sylvia Sangwa⁴, Catherine Ivory⁵, Elliot Hepworth¹ and Sibel Aydin⁶, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: There are discrepancies between physical examination and Ultrasound (US) in detecting inflammation in Rheumatoid Arthritis (RA). In this study, we aimed to understand, according…
Abstract Number: 0425 • ACR Convergence 2024
Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases
Antia Garcia Fernandez¹, Fernando Rengifo-Garcia¹, Raquel Senosiain-Echarte¹, Miguel Álvaro Navidad¹, Miguel Angel Gonzalez-Gay² and Juan Antonio Martínez - López¹, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain
Background/Purpose: Current recommendations advocate maintaining pregnancy-compatible bDMARDs during pregnancy (mainly TNF inhibitors) and monitoring disease activity before conception to improve disease and pregnancy outcomes. Recently,…
Abstract Number: 0531 • ACR Convergence 2024
Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort
Sama Hajizadeh¹, Tyson Barrett², Yue Yin³ and Dr Tarun Sharma⁴, ¹Allegheny Health Network, Pittsburgh, ²Enterprise Data and Analytics, Highmark Health, Pittsburgh, ³Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, ⁴West Penn Hospital, Pittsburgh, PA
Background/Purpose: Existing American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) guidelines regarding medication tapering in patients with rheumatoid arthritis (RA)…
Abstract Number: 0667 • ACR Convergence 2024
Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry
Takehiro HIrayama¹, Kohei Tsujimoto², Kayoko Kaneko³, Sakiko Isojima⁴, Kunihiro Ichinose⁵, Yasunori Iwata⁶, Kenji Oku⁷, Kenei Sada⁸, Yoshiya Tanaka⁹, Ayako Nakajima¹⁰, Keishi Fujio¹¹, Masakazu Matsushita¹², Takako Miyamae¹³, Atsuko Murashima³ and Atsushi Kumanogoh¹⁴, ¹Osaka university, Ibaraki City, Japan, ²Osaka University, Toyonaka, Osaka, Osaka, Japan, ³National Center for Child Health and Development, Setagaya, Tokyo, Japan, ⁴Showa Univeristy, Shinagawa, Tokyo, Japan, ⁵Shimane University, Izumo, Shimane, Japan, ⁶Kanazawa University, kanazawa, Japan, ⁷Kitazato University, Sagamihara, Kanagawa, Japan, ⁸Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ¹¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., TOKYO, Japan, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴Osaka University, Osaka, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse clinical manifestations and organ involvement, posing significant challenges in its management. The emergence…
Abstract Number: 0989 • ACR Convergence 2024
Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Mark Gibson¹, Benjamin Zuckerman², Maryam Adas¹, Mark Russell³, Katie Bechman¹ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College London, London, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…
Abstract Number: 1374 • ACR Convergence 2024
Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer
Roba Ghossan¹, Elodie Portier², OLIVIER FOGEL³, Sophie Hecquet¹, Astrid Dauchez¹, Omar AL TABAA⁴, Marion THOMAS⁵, Julia Herrou¹, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹COCHIN HOSPITAL, PARIS, France, ²Cochin Hospital, Bry sur Marne, France, ³AP-HP, Paris, France, ⁴APHP - Cochin Hospital, Paris, France, ⁵APHP, Paris, France, ⁶Université Paris Cité, Paris, France, ⁷Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Managing inflammatory arthritis patients on biologics with a history of cancer remains a complex task in daily rheumatology practice and requires a thoughtful, individualized…
Abstract Number: 1473 • ACR Convergence 2024
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
M. Elaine Husni¹, Philip Mease², Dafna Gladman³, Barbara Ink⁴, Jérémy Lambert⁵, Patrick Healy⁶ and Laure Gossec⁷, ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Colombes, France, ⁶UCB Pharma, Morrisville, NC, ⁷Sorbonne Université, Paris, France
Background/Purpose: PsA is characterized by joint and skin inflammation, and associated with debilitating symptoms of pain and fatigue.1 Previous research has shown that pain and…
Abstract Number: 1716 • ACR Convergence 2024
Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study
Kasra Moolooghy¹, Hui Xie², Yufei Zheng³, J. Antonio Avina-Zubieta¹ and Diane Lacaille¹, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Various classes of biologic and targeted synthetic DMARDs (b/tsDMARDs) are now available for treatment of inflammatory arthritis (IA), but little information on their relative…
Abstract Number: 2044 • ACR Convergence 2024
Clinical Practice Patterns, Rilonacept Appropriate Use for Recurrent Pericarditis
Jessica Farrell¹, Michael Allen², Lee Shapiro³, Victoria Michaels⁴, Arifa Javed⁵, Nabiha Qureshi⁶, Summia Matin Afridi⁷, Shahad Almahmoud⁸, Getzabeth Bosques Gomez⁹ and Khoa Richard Ngo¹⁰, ¹Albany College of Pharmacy & Health Sciences/Albany Medical Center, Delmar, NY, ²Albany Medical Center, Delmar, NY, ³Albany Medical College, Stillwater, NY, ⁴Albany Medical Center, Wynantskill, NY, ⁵Albany Medical Center, Rensselaer, NY, ⁶Albany Medical Center, Menands, NY, ⁷Albany Medical Center, Albany, NY, ⁸Albany College of Pharmacy & Health Sciences/Albany Medical Center, Albany, NY, ⁹Albany College of Pharmacy and Health Sciences/Albany Medical Center, Albany, NY, ¹⁰Albany Medical Center, Voorheesville, NY
Background/Purpose: Pericarditis is inflammation of the pericardial sac which can be of infectious or non-infectious etiology, commonly associated with rheumatic diseases. Pericarditis is defined as…
Abstract Number: 2353 • ACR Convergence 2024
Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Natalie J. Shiff⁴, Toby Thomas⁵, Emmanouil Rampakakis⁶, Francois Nantel⁷, Frederic Lavie⁸ and Proton Rahman⁹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ³University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Pharmaceuticals, Horsham, PA, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷Nantel MedSci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada
Background/Purpose: In the Phase 3 DISCOVER (D)-1 and -2 studies, guselkumab (GUS; IL-23p19-subunit inhibitor) 100 mg every 4 weeks (Q4W) or Q8W significantly improved joint…
Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…

1
2
3
…
54
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].